 |
31 Diseases |  |
34 Trials |
|
34 Trials |  |
1690 News |  |
| «12...78910111213141516171819» |
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment change, Trial termination, Trial primary completion date: Lina-Plaque: Effect of Linagliptin on Vascular Inflammation in Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Dec 4, 2015
P3, N=4, Terminated, Sponsor: RWTH Aachen University
N=60 --> 4 | Recruiting --> Terminated | Trial primary completion date: Mar 2016 --> Sep 2015; bad recruitment of suitable participants, just 4 patients in one year
- ||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment change: Linagliptin as Add on to Basal Insulin in the Elderly (clinicaltrials.gov) - Nov 19, 2015
P4, N=300, Recruiting, Sponsor: Boehringer Ingelheim
N=60 --> 4 | Recruiting --> Terminated | Trial primary completion date: Mar 2016 --> Sep 2015; bad recruitment of suitable participants, just 4 patients in one year N=800 --> 300
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
New trial: CANDY-CANE: Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management (clinicaltrials.gov) - Nov 18, 2015
P=N/A, N=24, Recruiting, Sponsor: University of Washington
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment closed: PMS of Trazenta on the Long-term Use as Add-on Therapy (clinicaltrials.gov) - Nov 17, 2015
P=N/A, N=3000, Active, not recruiting, Sponsor: Boehringer Ingelheim
N=800 --> 300 Recruiting --> Active, not recruiting
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment closed, Trial primary completion date, Monotherapy: Off taRget Effects of Linagliptin monothErapy on Arterial Stiffness in Early Diabetes (clinicaltrials.gov) - Oct 29, 2015
P3, N=40, Active, not recruiting, Sponsor: dr. DJ Mulder
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Jan 2016
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment change, Trial initiation date: A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers (clinicaltrials.gov) - Oct 27, 2015
P4, N=160, Not yet recruiting, Sponsor: National Taiwan University Hospital
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Jan 2016 N=400 --> 160 | Initiation date: Apr 2015 --> Oct 2015
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment change, Trial termination: IMPERIUM: A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM) (clinicaltrials.gov) - Oct 22, 2015
P4, N=193, Terminated, Sponsor: Eli Lilly and Company
N=400 --> 160 | Initiation date: Apr 2015 --> Oct 2015 N=880 --> 193 | Active, not recruiting --> Terminated; The trial was terminated per protocol because of lack of feasibility.
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial primary completion date: Effects of Linagliptin on Endothelial Function (clinicaltrials.gov) - Oct 5, 2015
P4, N=50, Recruiting, Sponsor: Medical University of Graz
N=880 --> 193 | Active, not recruiting --> Terminated; The trial was terminated per protocol because of lack of feasibility. Trial primary completion date: Jul 2015 --> Apr 2016
- ||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment closed: IMPERIUM: A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM) (clinicaltrials.gov) - Sep 25, 2015
P4, N=880, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Jul 2015 --> Apr 2016 Recruiting --> Active, not recruiting
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial primary completion date: IMPERIUM: A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM) (clinicaltrials.gov) - Sep 24, 2015
P4, N=880, Recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2016 --> Oct 2015
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial primary completion date: Linagliptin as Add on to Basal Insulin in the Elderly (clinicaltrials.gov) - Aug 21, 2015
P4, N=800, Recruiting, Sponsor: Boehringer Ingelheim
Trial primary completion date: Apr 2016 --> Oct 2015 Trial primary completion date: Mar 2016 --> Nov 2016
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial primary completion date: IMPERIUM: A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM) (clinicaltrials.gov) - Aug 21, 2015
P4, N=880, Recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Mar 2016 --> Nov 2016 Trial primary completion date: Apr 2018 --> Apr 2016
- | Apleway (tofogliflozin) / Kowa, Takeda, Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Lusefi (luseogliflozin) / Taisho
New P4 trial: Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors (clinicaltrials.gov) - Aug 19, 2015
P4, N=100, Recruiting, Sponsor: Kurume University
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Byetta (exenatide) / AstraZeneca
Enrollment open, Trial primary completion date: SAFEGUARD: Safety Evaluation of Adverse Reactions in Diabetes (clinicaltrials.gov) - Aug 11, 2015
P4, N=60, Recruiting, Sponsor: Charles University, Czech Republic
Trial primary completion date: Apr 2018 --> Apr 2016 Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2014 --> Nov 2015
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial primary completion date: Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes (clinicaltrials.gov) - Jul 20, 2015
P2, N=117, Recruiting, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2014 --> Nov 2015 Trial primary completion date: May 2016 --> Jan 2016
- | DW 1029M / Dong Wha
Trial completion: PLID: the Pharmacokinetic Profiles of Linagliptin With DW1029M (clinicaltrials.gov) - Jun 29, 2015
P1, N=12, Completed, Sponsor: Dong Wha Pharmaceutical Co. Ltd.
Trial primary completion date: May 2016 --> Jan 2016 Active, not recruiting --> Completed
- ||||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment closed: MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin (clinicaltrials.gov) - Jun 26, 2015
P3, N=350, Active, not recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial primary completion date: Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes (clinicaltrials.gov) - Jun 17, 2015
P2, N=117, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2015 --> May 2016
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment change: Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin (clinicaltrials.gov) - Jun 16, 2015
P=N/A, N=500000, Recruiting, Sponsor: Boehringer Ingelheim
Trial primary completion date: Dec 2015 --> May 2016 N=250000 --> 500000
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
New P4 trial: Linagliptin's Effect on CD34+ Stem Cells (clinicaltrials.gov) - Jun 10, 2015
P4, N=40, Recruiting, Sponsor: George Washington University
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
New P4 trial: Linagliptin and Mesenchymal Stem Cells: A Pilot Study (clinicaltrials.gov) - May 13, 2015
P4, N=8, Recruiting, Sponsor: University of Nevada, Reno
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Clinical: Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology (clinicaltrials.gov) - May 7, 2015
P4, N=44, Recruiting, Sponsor: Profil Institut für Stoffwechselforschung GmbH
N=250000 --> 500000 Not yet recruiting --> Recruiting | Trial primary completion date: Aug 2015 --> Nov 2015
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
New P4 trial: A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers (clinicaltrials.gov) - Apr 29, 2015
P4, N=400, Not yet recruiting, Sponsor: National Taiwan University Hospital
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial primary completion date: Linagliptin in Schizophrenia Patients (clinicaltrials.gov) - Apr 20, 2015
P1, N=5, Recruiting, Sponsor: Monash University
Not yet recruiting --> Recruiting | Trial primary completion date: Aug 2015 --> Nov 2015 Trial primary completion date: Oct 2014 --> Oct 2016
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Clinical: Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology (clinicaltrials.gov) - Apr 2, 2015
P4, N=44, Not yet recruiting, Sponsor: Profil Institut für Stoffwechselforschung GmbH
- |||| Gemiglo (gemigliptin) / Sanofi, LG Chem
Phase classification, Trial primary completion date: A Phase IIIb Study to Evaluate the Safety and Efficacy of Gemigliptin in Type 2 Diabetes Mellitus Patients With Moderate or Severe Renal Impairment(GUARD Study) (clinicaltrials.gov) - Mar 14, 2015
P3, N=148, Recruiting, Sponsor: LG Life Sciences
Trial primary completion date: Oct 2014 --> Oct 2016 Phase classification: P4 --> P3 | Trial primary completion date: Jul 2014 --> Dec 2015
- Enrollment open, Trial primary completion date: Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments. (clinicaltrials.gov) - Mar 12, 2015
P=N/A, N=50, Recruiting, Sponsor: Erasme University Hospital
Phase classification: P4 --> P3 | Trial primary completion date: Jul 2014 --> Dec 2015 Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2015 --> Oct 2016
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment change: Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin (clinicaltrials.gov) - Mar 7, 2015
P=N/A, N=250000, Recruiting, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2015 --> Oct 2016 N=200000 --> 250000
- ||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
New P3 trial: Effects of Linagliptin on Endothelial- , Renal-, and Retinal Function in Patients With Hypertension and Albuminuria (clinicaltrials.gov) - Mar 3, 2015
P3, N=43, Completed, Sponsor: ikfe-CRO GmbH
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
New P4 trial: The Effect of LINAGLIPTIN on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects (clinicaltrials.gov) - Feb 26, 2015
P4, N=40, Recruiting, Sponsor: Kaleida Health
- DW 1029M / Dong Wha
Enrollment closed: PLID: the Pharmacokinetic Profiles of Linagliptin With DW1029M (clinicaltrials.gov) - Feb 12, 2015
P1, N=12, Active, not recruiting, Sponsor: Dong Wha Pharmaceutical Co. Ltd.
N=200000 --> 250000 Enrolling by invitation --> Active, not recruiting
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment change, Trial termination, Trial primary completion date: Diastolic Dysfunction in Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Feb 10, 2015
P3, N=8, Terminated, Sponsor: RWTH Aachen University
Enrolling by invitation --> Active, not recruiting N=60 --> 8 | Recruiting --> Terminated | Trial primary completion date: Apr 2015 --> Dec 2014; bad recruitment of suitable participants, just 8 patients in one year
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial primary completion date: The Effect of Linagliptin on Mitochondrial and Endothelial Function (clinicaltrials.gov) - Feb 5, 2015
P4, N=40, Recruiting, Sponsor: Beth Israel Deaconess Medical Center
N=60 --> 8 | Recruiting --> Terminated | Trial primary completion date: Apr 2015 --> Dec 2014; bad recruitment of suitable participants, just 8 patients in one year Trial primary completion date: Dec 2014 --> Jul 2016
- ||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial initiation date: Linagliptin as Add on to Basal Insulin in the Elderly (clinicaltrials.gov) - Feb 5, 2015
P4, N=800, Recruiting, Sponsor: Boehringer Ingelheim
Trial primary completion date: Dec 2014 --> Jul 2016 Initiation date: Jan 2014 --> Sep 2014
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
New P4 trial: Effects of Linagliptin on Endothelial Function (clinicaltrials.gov) - Jan 29, 2015
P4, N=50, Recruiting, Sponsor: Medical University of Graz
- ||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial initiation date: Linagliptin as Add on to Basal Insulin in the Elderly (clinicaltrials.gov) - Jan 26, 2015
P4, N=800, Recruiting, Sponsor: Boehringer Ingelheim
Initiation date: Jan 2014 --> Sep 2014 Initiation date: Sep 2014 --> Jan 2014
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment change: Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin (clinicaltrials.gov) - Jan 22, 2015
P=N/A, N=200000, Recruiting, Sponsor: Boehringer Ingelheim
Initiation date: Sep 2014 --> Jan 2014 N=120000 --> 200000
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment open: DPP-4 Inhibitor and Serum BNP Level of Diabetic Patients With Congestive Heart Failure (clinicaltrials.gov) - Jan 12, 2015
P4, N=50, Recruiting, Sponsor: Mitsui Memorial Hospital
N=120000 --> 200000 Not yet recruiting --> Recruiting
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
New P3 trial: Early Prevention of Diabetes Complications in people with Pre-Diabetes in Europe Prevenci (EUDRACT) - Dec 19, 2014
P3, N=3000, Ongoing, Sponsor: FUNDACION DE INVESTIGACION EN RED EN ENFERMEDADES
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment open: ADA Linagliptin in Long Term Care (clinicaltrials.gov) - Dec 19, 2014
P4, N=150, Recruiting, Sponsor: Emory University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial completion, Enrollment change, Trial primary completion date: Rapid Effects Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 Diabetes (clinicaltrials.gov) - Dec 19, 2014
P4, N=45, Completed, Sponsor: University of Padova
Not yet recruiting --> Recruiting Recruiting --> Completed | N=60 --> 45 | Trial primary completion date: Sep 2014 --> Dec 2014
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
New P4 trial: DPP-4 Inhibitor and Serum BNP Level of Diabetic Patients With Congestive Heart Failure (clinicaltrials.gov) - Dec 10, 2014
P4, N=50, Not yet recruiting, Sponsor: Mitsui Memorial Hospital
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment open, Trial primary completion date: Effects of Linagliptin on Active GLP-1 Concentrations in Subjects With Renal Impairment (clinicaltrials.gov) - Dec 6, 2014
P4, N=30, Recruiting, Sponsor: Profil Institut f
Recruiting --> Completed | N=60 --> 45 | Trial primary completion date: Sep 2014 --> Dec 2014 Active, not recruiting --> Recruiting | Trial primary completion date: Dec 2014 --> Jan 2016
- DW 1029M / Dong Wha
Enrollment open, Trial initiation date, Trial primary completion date: PLID: the Pharmacokinetic Profiles of Linagliptin With DW1029M (clinicaltrials.gov) - Dec 5, 2014
P1, N=12, Enrolling by invitation, Sponsor: Dong Wha Pharmaceutical Co. Ltd.
Active, not recruiting --> Recruiting | Trial primary completion date: Dec 2014 --> Jan 2016 Not yet recruiting --> Enrolling by invitation | Initiation date: Aug 2014 --> Nov 2014 | Trial primary completion date: Oct 2014 --> Jan 2015
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment closed: Effects of Linagliptin on Active GLP-1 Concentrations in Subjects With Renal Impairment (clinicaltrials.gov) - Nov 13, 2014
P4, N=30, Active, not recruiting, Sponsor: Profil Institut f
Not yet recruiting --> Enrolling by invitation | Initiation date: Aug 2014 --> Nov 2014 | Trial primary completion date: Oct 2014 --> Jan 2015 Enrolling by invitation --> Active, not recruiting
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment open, Trial initiation date, Trial primary completion date: Lina-Plaque: Effect of Linagliptin on Vascular Inflammation in Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Nov 5, 2014
P3, N=60, Recruiting, Sponsor: RWTH Aachen University
Enrolling by invitation --> Active, not recruiting Not yet recruiting --> Recruiting | Initiation date: Apr 2014 --> Aug 2014 | Trial primary completion date: Jun 2015 --> Mar 2016
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
New P4 trial: Effect of Linagliptin on TRL Metabolism (clinicaltrials.gov) - Oct 31, 2014
P4, N=20, Recruiting, Sponsor: Ministry of Public Health, Argentina
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment status: Effects of Linagliptin on Active GLP-1 Concentrations in Subjects With Renal Impairment (clinicaltrials.gov) - Oct 31, 2014
P4, N=30, Enrolling by invitation, Sponsor: Profil Institut f
Not yet recruiting --> Recruiting | Initiation date: Apr 2014 --> Aug 2014 | Trial primary completion date: Jun 2015 --> Mar 2016 Recruiting --> Enrolling by invitation
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment status: Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA) (clinicaltrials.gov) - Oct 21, 2014
P4, N=8300, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Enrolling by invitation Recruiting --> Recruiting
- |||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment open: Linagliptin as Add on to Basal Insulin in the Elderly (clinicaltrials.gov) - Oct 10, 2014
P4, N=800, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Recruiting Not yet recruiting --> Recruiting